Existence of monomer and dimer forms of mGluR5, under reducing conditions in studies of postmortem brain in various psychiatric disorders

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 270-271

  Fatemi, S Hossein ^a   Folsom, Timothy D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; METABOTROPIC RECEPTOR 5; MONOMER;

AGE; AUTISM; AUTOPSY; BIPOLAR DISORDER; FRAGILE X SYNDROME; HUMAN; LETTER; MAJOR DEPRESSION; MENTAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; PROTEIN CONFORMATION; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84906936504     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.029     Document Type: Letter

References (10)

1. Corti C., Crepaldi L., Mion S., Roth A.L., Xuereb J.H., Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry 2007, 62(7):747-755.
2. El Moustaine D., Granier S., Doumazane E., Scholler P., Rahmeh R., Bron P., Mouillac B., Banères J.L., Rondard P., Pin J.P. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(40):16342-16347.
3. Fatemi S.H., Folsom T.D. Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol. Autism 2011, 2:6.
4. Fatemi S.H., Folsom T.D., Kneeland R.E., Liesch S.B. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat. Rec. 2011, 294(10):1635-1645.
5. Fatemi S.H., Folsom T.D., Rooney R.J., Thuras P.D. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl. Psychiatry 2013, 3:e271.
6. Hermans E., Challiss R.A. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem. J. 2001, 359(Pt 3):465-484.
7. Manahan-Vaughan D., Ngomba R.T., Storto M., Kulla A., Catania M.V., Chiechio S., Rampello L., Passarelli F., Capece A., Reymann K.G., Nicoletti F. An increased expression of the mGlu5 receptor protein following LTP induction at the perforant path-dentate gyrus synapse in freely moving rats. Neuropharmacology 2003, 44(1):17-25.
8. Matosin N., Frank E., Deng C., Huang X.F., Newell K.A. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr. Res. 2013, 146(1-3):170-176.
9. Newell K.A., Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry 2014, 14:23.
10. Romano C., Yang W.-L., O'Malley K.L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 1996, 271(45):28612-28616.